[O19] Oral Session 19　TR・臨床薬理
【E】

[O19-6] Dose Selection for DuoBody^®-PD-L1x4-1BB (GEN1046) Using a Semimechanistic PK/PD Model Based on Preclinical/Clinical Data

^○Gaurav Bajaj⁵, Fereshteh Nazari², Marc Presler², Craig Thalhauser⁵, Ulf Forssmann³, Maria Jure-Kunkel⁵, Alexander Muik⁴, Eleni Lagkadinou⁴, Özlem Türeci⁴, Uğur Şahin⁴, Tahamtan Ahmadi⁵, Manish Gupta⁵ (1.Genmab, 2.Applied BioMath LLC, Concord, MA, USA, 3.Genmab A/S, Copenhagen, Denmark, 4.BioNTech SE, Mainz, Germany, 5.Genmab, Princeton, NJ, USA)